 Home > Active Ingredient News > Antitumor Therapy > Hengrui Medicine's application for the listing of CDK 4/6 inhibitors has been accepted and R&D investment nearly 2...

Hengrui Medicine's application for the listing of CDK 4/6 inhibitors has been accepted and R&D investment nearly 2...

 Last Update: 2021-05-10
 Source: Internet
 Author: User

Tags

spiriva drug class

drug test cbd

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Source: Guanlan Pharmaceutical

On April 27, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Hengrui Medicine's Class 1 new drug CDK 4/6 inhibitor SHR6390 tablets had submitted a new drug marketing application and was accepted.

Screenshot source: CDE official website

CDK 4/6 (cyclin-dependent kinase 4 and 6) is a key regulator that drives cell division.

SHR6390 is an oral, high-efficiency and selective small molecule CDK 4/6 inhibitor developed by Hengrui Medicine, which is a Class 1 new drug.

On March 17, SHR6390 tablets were included in the CDE breakthrough treatment category announcement.

Screenshot source: CDE official website

Public information shows that SHR6390 has reached the pre-designated superiority standard in a multi-center, randomized, controlled, double-blind phase 3 clinical study named SHR6390-III-301.

It is reported that in addition to the second-line treatment of hormone receptor-positive breast cancer, SHR6390 is also undergoing key research on its application in advanced first-line related treatments.

Breast cancer is the most common cancer among women worldwide.

According to the announcement issued by Hengrui Medicine on April 26, the world’s approved CDK 4/6 inhibitors include palbociclib (trade name: Ibrance) developed by Pfizer and ribociclib (trade name: Novartis) developed by Novartis.

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.